Giulia Arrivi | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Resectable gastric cancer: should we apply a tailored surgical strategy according to microsatellite status?	JOURNAL OF GASTROINTESTINAL SURGERY	2025
The efficacy of streptozotocin in managing pancreatic neuroendocrine neoplasms – A systematic review	CANCER TREATMENT REVIEWS	2025
Cabozantinib in the Treatment of Neuroendocrine Neoplasms: Insights across Different Tumor Origins	NEUROENDOCRINOLOGY	2025
Diagnostic and Therapeutic Management of Primary Orbital Neuroendocrine Tumors (NETs): Systematic Literature Review and Clinical Case Presentation	BIOMEDICINES	2024
Is CT Radiomics Superior to Morphological Evaluation for pN0 Characterization? A Pilot Study in Colon Cancer	CANCERS	2024
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis	TARGETED ONCOLOGY	2024
Leptomeningeal Carcinomatosis in Early Gastric Cancer: A Case Report and Literature Review	HEALTHCARE	2024
Management of overlapping immune-related myocarditis, myositis, and myasthenia in a young patient with advanced NSCLC: a case report	FRONTIERS IN ONCOLOGY	2024
73P Efficacy outcomes in ≥70-year-old or younger patients receiving regorafenib-to-trifluridine/tipiracil sequence or vice versa for refractory metastatic colorectal cancer: Findings from the multicenter retrospective “ReTrITA” study	ANNALS OF ONCOLOGY	2024
Survival benefit with regorafenib and/or trifluridine/tipiracil sequencing to rechallenge with anti-EGFR-based third-line regimens in metastatic colorectal cancer: A multicenter retrospective real-world subgroups comparison	JOURNAL OF CLINICAL ONCOLOGY	2024
Exploring carcinoid syndrome in neuroendocrine tumors: insights from a multidisciplinary narrative review	CANCERS	2024
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study	CURRENT ONCOLOGY	2024
Sidedness and Molecular Pattern in Defining the Risk of Lymph Node Metastasis in Nonmetastatic Colorectal Cancer: Single-Center Retrospective Study	CANCERS	2024
258P The impact of total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC): A real-world Italian multicentric experience	ANNALS OF ONCOLOGY	2024
Sequential treatment with regorafenib and trifluridine/tipiracil in later-line refractory metastatic colorectal cancer: A real-world multicenter retrospective study	JOURNAL OF CLINICAL ONCOLOGY	2023
The management of oligometastatic disease in colorectal cancer: present strategies and future perspectives	CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY	2023
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study	CURRENT ONCOLOGY	2023
The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets	FRONTIERS IN ONCOLOGY	2023
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis	CANCERS	2023
P-195 Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study	ANNALS OF ONCOLOGY	2023